ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
Anavex Life Sciences Corporation

Anavex Life Sciences Corporation (AVXL)

8.185
0.115
( 1.43% )
업데이트: 03:04:55

행사 가격매수가매도가최근 가격중간 가격가격 변동가격 변동 %거래량미결제 약정최근 거래
2.006.006.500.006.250.000.00 %00-
3.005.005.300.005.150.000.00 %00-
4.004.004.300.004.150.000.00 %00-
5.003.103.303.383.200.000.00 %020-
6.002.002.403.032.200.000.00 %01-
7.001.351.502.181.4250.000.00 %02-
8.000.700.800.790.75-0.02-2.47 %19802:20:34
9.000.200.400.460.300.0615.00 %154401:08:15
10.000.150.250.200.200.000.00 %0297-
11.000.100.200.100.150.000.00 %0110-
12.000.050.150.070.100.000.00 %145702:01:28
13.000.050.100.050.0750.000.00 %0125-
14.000.050.100.050.0750.000.00 %5934700:15:38
15.000.100.450.100.2750.000.00 %030-
16.000.180.300.180.240.000.00 %0101-
17.000.050.200.050.1250.000.00 %0299-

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

행사 가격매수가매도가최근 가격중간 가격가격 변동가격 변동 %거래량미결제 약정최근 거래
2.000.000.500.000.000.000.00 %00-
3.000.000.500.000.000.000.00 %00-
4.000.050.500.050.2750.000.00 %010-
5.000.050.500.050.2750.000.00 %020-
6.000.100.150.100.1250.000.00 %0100-
7.000.200.250.250.2250.000.00 %949601:05:50
8.000.550.600.550.575-0.15-21.43 %939201:05:50
9.001.151.251.201.200.000.00 %0116-
10.001.952.151.722.050.000.00 %039-
11.002.853.003.002.9250.000.00 %05-
12.003.804.004.003.900.000.00 %020-
13.004.505.100.004.800.000.00 %00-
14.005.506.100.005.800.000.00 %00-
15.006.507.000.006.750.000.00 %00-
16.007.508.000.007.750.000.00 %00-
17.008.509.000.008.750.000.00 %00-

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
BCGBinah Capital Group Inc
US$ 3.77
(102.88%)
46.65M
ULYUrgent ly Inc
US$ 0.6725
(60.12%)
139.56M
ESGLESGL Holdings Ltd
US$ 1.60
(60.00%)
41.2M
PEPGPepGen Inc
US$ 2.25
(47.06%)
4.66M
XNETXunlei Ltd
US$ 4.02
(38.62%)
46.59M
SUNESUNation Energy Inc
US$ 0.4413
(-61.63%)
4.22M
SPGCSacks Parente Golf Inc
US$ 0.4575
(-37.51%)
6.72M
DMRCDigimarc Corporation
US$ 17.10
(-36.76%)
1.02M
ARKOARKO Corporation
US$ 4.708
(-35.15%)
4.26M
TNDMTandem Diabetes Care Inc
US$ 22.505
(-33.00%)
7.96M
NVDANVIDIA Corporation
US$ 127.41
(-2.95%)
235.07M
QNRXQuoin Pharmaceuticals Ltd
US$ 0.3647
(18.49%)
143.55M
ULYUrgent ly Inc
US$ 0.6725
(60.12%)
139.56M
TRNRInteractive Strength Inc
US$ 1.46
(16.80%)
121.92M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 13.11
(-1.35%)
103.41M

AVXL Discussion

게시물 보기
rx7171 rx7171 1 시간 전
Without an explanation of the methodology where the $325 million net profit comes from so it is hard to take this seriously.

However I’ve seen an analysis from a mainline investor service that sees a $5.11 per share profit in 2026. Obviously in anticipation of a EMA approval and sales in the EU.
With 80 million outstanding shares that comes to about $400 million for the year, not far off the $325.
🎯 2 👍️ 4 😃 1
found_it2 found_it2 2 시간 전
Yeah, true that, but I will be buying again if it drops below 8, just waiting for my entry point...missed that 7.95 the other day, was out of town...
Anything under 10 in the very near future will seem like a bargain - this company is worth the wait.
👍️ 1 😃 1
ExtremelyBullishZig ExtremelyBullishZig 2 시간 전
Lol...how bout those prices...could have bought at $8. And lower later.
👎️ 1 👺 1
LakeshoreLeo1953 LakeshoreLeo1953 2 시간 전
Certainly sounds like confirmation of Febish!!!!!
👍️ 1 👎️ 2 👺 2
LakeshoreLeo1953 LakeshoreLeo1953 2 시간 전
Am I correct that
The obvious immediate application would be concussion (infer Sports injuries)?
👍️0
found_it2 found_it2 2 시간 전
"Anavex Life Sciences Corp. (NASDAQ:AVXL) Is Expected To Breakeven In The Near Future"

editorial-team@simplywallst.com (Simply Wall St)
Thu, February 27, 2025 at 4:50 AM PST

Anavex Life Sciences Corp. (NASDAQ:AVXL) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases in the United States.
The company’s loss has recently broadened since it announced a US$43m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$46m, moving it further away from breakeven.
The most pressing concern for investors is Anavex Life Sciences' path to profitability – when will it breakeven? We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.

Consensus from 3 of the American Biotechs analysts is that Anavex Life Sciences is on the verge of breakeven. They anticipate the company to incur a final loss in 2025, before generating positive profits of US$325m in 2026. So, the company is predicted to breakeven just over a year from today. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 50%, which is extremely buoyant. Should the business grow at a slower rate, it will become profitable at a later date than expected.

earnings-per-share-growth
NasdaqGS:AVXL Earnings Per Share Growth February 27th 2025
Underlying developments driving Anavex Life Sciences' growth isn’t the focus of this broad overview, but, take into account that typically a biotech has lumpy cash flows which are contingent on the product type and stage of development the company is in. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.

Before we wrap up, there’s one aspect worth mentioning. Anavex Life Sciences currently has no debt on its balance sheet, which is quite unusual for a cash-burning biotech, which usually has a high level of debt relative to its equity. This means that the company has been operating purely on its equity investment and has no debt burden. This aspect reduces the risk around investing in the loss-making company.

Next Steps:
There are too many aspects of Anavex Life Sciences to cover in one brief article, but the key fundamentals for the company can all be found in one place – Anavex Life Sciences' company page on Simply Wall St. We've also put together a list of key aspects you should look at:

Historical Track Record: What has Anavex Life Sciences' performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.

Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Anavex Life Sciences' board and the CEO’s background.
🎯 2 👍️ 5 😃 1
oldmystic oldmystic 3 시간 전
Tizzy gettin dizzy Doc
https://www.nature.com/articles/s41593-025-01877-7
https://invst.ly/197dwe
👍️ 1
LakeshoreLeo1953 LakeshoreLeo1953 3 시간 전
If his personal door to knowledge only swings one way....
How do you expect ANY theory which he can explain for his position
(real or not)?
👍️ 1 👎️ 1 👺 1
LakeshoreLeo1953 LakeshoreLeo1953 3 시간 전
IF your takeaway from the cited "quote" is that management says it knows
Blarcamesine is a success we just have to await the EMA decision....
That is exactly what the quote believes is NOT being said.
Whether approval is coming or not, NOTHING that the shareholder posited
is a management confirmation.
👍️ 2 👎️ 1 👺 1
ExtremelyBullishZig ExtremelyBullishZig 6 시간 전
Well....it remains safe...not all endpoints (especially the failed primary endpoints) or the placebo arm point to effective for AD...and definitely not effective for Rett. Trials for PD took forever to get going and still aren't started...What are they hiding?
👎️ 3 👺 2
williamssc williamssc 16 시간 전
Blarcamesine remains safe and effective while AD is still an unmet need. The EMA encouraged Anavex to go the pathway of full approval. Tutes are now steady increasing. The days of knocking on the CEO are getting shorter. I also added today..All and all seems like very good odds for EMA approval.
🏆️ 4 👍️ 34 👏 4 😃 1 🧠 1 ✈️ 1
kund kund 17 시간 전
There are SEC rules for an officer of a company pumping a stock with false information. That’s exactly what the commenter is pointing out—TGD continues to provide false information in every conference without facing any accountability. He’s emboldened because neither the SEC nor shareholders can take action, yet shareholders keep losing their hard-earned money due to his constant pumping with false information. He has been posting on LinkedIn for the past month, repeating the same information and then adding, "The following might be relevant in this context." What does that even mean? Instead of wasting time on LinkedIn, he should focus on getting the drug approved by the FDA. The FDA isn’t going to invite him to file an NDA—it’s his responsibility. And for a $4-5 million salary per year, he’s doing a lousy job.

The AD Phase 2a trial was completed in 2015, and the Phase 2b/3 trial started in 2018—meaning he took three years just to design another tiny trial. The trial itself took four years to complete, and then another 2.5 years to release junk data. In total, he has spent 10 years on the Phase 2b/3 trial.
👍️ 3 👎️ 4 👺 1
williamssc williamssc 18 시간 전
I did see this comment from a share holder-- Exactly... we don't know what we don't know... Team Anavex does know.
There are SEC rules for an officer of a company pumping a stock with false information. This team is very cautious and conservative. They want to get the approvals on the first try and won't tip their hand just to appease anxious press or shareholders. If you believe in their work, hold tight. If not, just look at another investment. Simple...

In other words Anavex has the goods and are holding their cards close.
🏆️ 3 👍️ 21 😃 1 🧠 1
georgejjl georgejjl 18 시간 전
Mitochondrial autophagy in the sleeping brain

https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2022.956394/full

Good luck and GOD bless,
🏆️ 1 👍️ 6 👏 1 🧠 1
mike_dotcom mike_dotcom 18 시간 전
I don't pretend to know where it might get support. It's down over 40% in one month so the trend is down and that's what this stock does best. I don't see any news on the horizon to change the trend. I'd love to be surprised but we NEVER get positive surprises.
👍️ 1 👎️ 2 👺 2 🫤 1
georgejjl georgejjl 18 시간 전
There's a Critical Thing We Can All Do to Keep Alzheimer's Symptoms at Bay

DEEP SLEEP

https://www.sciencealert.com/theres-a-critical-thing-we-can-all-do-to-keep-alzheimers-symptoms-at-bay

Autophagy!!!

Good luck and GOD bless,
👍️ 3 🙌 1
123tom 123tom 18 시간 전
If you're that sure, then you ought to be able to see the targets. What support targets are you seeing?
👍️ 2
BIOChecker4 BIOChecker4 19 시간 전
No wonder Missling has stopped talking about Rett syndrome. You snooze, you lose. https://www.neurenpharma.com/showdownloaddoc.aspx?AnnounceGuid=4a5788b5-472b-452b-9007-fda2b88ca46f
👎️ 2 👺 2
kund kund 19 시간 전
More comments on same post. It's good to see people calling out the Clown CEO for his misleading statements. I suspect he'll stop posting on LinkedIn and revert to his usual dog-and-pony shows.

maybe the FDA did advise them not to apply yet, maybe they didn't, we don't know because the company doesn't communicate with shareholders, and when it (Missling) does it usually states that the company will do something that it doesn't end up doing. You don't think there's any issue with Missling saying on January 16th there would be an update on Parkinsons before the end of January and at the ASM meeting saying that within the week there would be an update on Rett, and that was almost a year ago but still nothing? And the FDA guidelines haven't changed since Missling said he was going to 'aggressively pursuing FDA approval', but at that point in time he was also claiming the trial had met both primary endpoints, and we all know how factual that turned out to be.... Sorry that I think he should be accountable for the words that come out of his own mouth.
👍️ 1 👎️ 2 👺 2
georgejjl georgejjl 20 시간 전
Look at the price chart today!!! It is absolutely obvious that the bashers, FUDsters and shorters painted the tape at eh close!!!

Good luck and GOD bless,
👍️ 1 🤓 1 🥸 1
mike_dotcom mike_dotcom 20 시간 전
I don't short stocks. If I was short this stock don't you think I'd be bragging about it? I learned my lesson a long long time ago. Now if only Anavex could produce some sort of actual news to scare the shorts. Since that awesome JPM conference the shorts have just become more emboldened. 58 leading scientists verifying the drug also emboldened them.
👍️ 1
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 20 시간 전
Wow, didn't know you had that much firepower, Mike.

Impressive. Thanks for the 4% on the borrowed shares.
👍️ 4
mike_dotcom mike_dotcom 20 시간 전
SHORT INTEREST ROSE TO HIGHEST LEVEL EVER -
Settlement Date Short Interest Avg. Daily Share Volume Days to Cover
02/14/2025 24,204,459 1,043,018 23.206176
01/31/2025 23,425,067 1,346,756 17.393698
👎️ 1
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 20 시간 전
comment on Misleading's LinkedIn post. People are showing their frustration

been complaining that things are glacial for years, no sense of urgency.

Even if you accept the reasonable proposition that AVXL should hold off the FDA filing until EMA approval, it doesn't explain the YEARS of total inaction on PD after supposed great results, or the total failure to do another Rett trial, an Epilepsy trial or that teased rare disease trial now 5 years promised and not delivered.

Good to see him get pushback.
👍️ 2
Hoskuld Hoskuld 21 시간 전
I usually think derivative market makers are a little ahead of the market as a whole and IV for the March puts is not huge. I don't know what will happen, but it doesn't look at the moment like there is an expectation that AVXL will drop to $7. FWIW, I wouldn't mind that in the short term - would generate quite a lot of cash for a month or two.
👍️ 2
ohsaycanyousee82 ohsaycanyousee82 22 시간 전
Sure Champ.
👍️ 2
mike_dotcom mike_dotcom 22 시간 전
Unfortunately I have not sold. Sure wish I'd have taken everyone's advice and dumped this dogschitt. And I'll probably regret not selling now.
👎️ 3
oldmystic oldmystic 23 시간 전
Don't sleep on Tizzy, Doc

https://www.tizianalifesciences.com/news/
TLSA M DeMark: https://invst.ly/196b3-
👍️ 1
ohsaycanyousee82 ohsaycanyousee82 23 시간 전
There is no doubt in DotCon’s mind that the price is going down so he has sold. Until further notice, he owns no shares.
👍️ 2
Cpap21 Cpap21 23 시간 전
Didn't your wife tell you to quit playing with her money before you lose it like you lost yours .
No wonder you are such a negative little man . Take a break and get off this board. You have your wife's money in with Missling, now let it ride !!
👍️ 3 🤣 3
mike_dotcom mike_dotcom 23 시간 전
We're back to the point where you can sell this dogschitt on any 10 cent bounce. If you get a 20 cent bounce it moves to STRONG SELL and if you're lucky enough to get a 30 cent bounce like today it moves to a SCREAMING STRING SELL. Oh, and whatever gain we have today (if we actually have one) will be given back tomorrow.
👎️ 1
mike_dotcom mike_dotcom 23 시간 전
It's going down. Not a doubt in my mind.
👎️ 1
123tom 123tom 24 시간 전
Yes, we're looking at the fine details now.
Low volume today, so far.
I'm inclined to think these bounces off the 8.00 step haven't been too spectacular. The first one of 55 cents was ok, but it tumbled right back down. Now today's bounce was even weaker and low volume. If that suggests any message... maybe it's that
buyers/ investors are not eager to jump in at 8 dollars. And on the chart, 8 dollars has been a significant price point in the past. People bought at 10, and 9, but now at 8 we're seeing lackluster interest. This doesn't sound bullish. My bias is looking still downward , neutral/bearish, targets in the 7's. Unless we see a big jump at 8 dollars with good volume.and rallies to 9 and higher.
👍️ 2
Hoskuld Hoskuld 1 일 전
Totally understand, BAR123. Another exec would not temper the puffery - puffery is pretty much all executives have until a product is approved. Like you, I also want the real story. I have been shocked at the blatant falsehoods that have been put forward after the safe harbor statement has been read. But, that is on me because I know that post-SH is fairy tale time. Most execs don't push it as far as CM has. Still, there is an MAA on file and that is not puffery. And there is a P2 readout for 3-71 coming, and that is not puffery.

If you have been in this from 2015 then probably you have done very well so far. I am more recent - 4 years ago was first small position? Now up to 300,000 shares. I think this will have been worth the wait, but you never know...
👍️ 2
Citrati Citrati 1 일 전
Interesting. Here is a 5 year weekly chart.
How easy was it to buy at 4 and sell at 14?
In 4 plus years there has only been 1 opportunity to do that and one would have had to hold for 3 months and through 2 consolidation periods. Your easy peasy would have been a poor return as opposed to the many smaller opportunities added up that would have given free shares to hold with minimal risk. I much prefer to buy excess lows at the the bottom BB and selling at the excess highs of the top BB while waiting for approvals.

Not to mention if you were waiting to buy at 4 and sell at 14 you would have missed the pops to 31.50, 23.73, 13.39 twice etc, etc. Pretty standard pattern for emerging bios and the many years it takes to progress from pre-clinical to the end of clinical trials for final approval.

All IMO only.

https://investorshub.advfn.com/uimage/uploads/2025/2/26/pzwihScreen_Shot_2025-02-26_at_9.52.26_AM.png
👍 2
kund kund 1 일 전
This is weird...comment on Misleading's LinkedIn post. People are showing their frustration with his constant lies on social media....


This might sound completely crazy, but what if you actually applied to the FDA for approval so that people can access this treatment, instead of just claiming daily how effective the treatment is. I know you're probably thinking, 'Hey, it's only been 32 months since we completed the trial, slow down there Seabiscuit', but actually applying for approval is so crazy, it just might work. Or since you seem to have an abundance of time on your hands, could we get an update on the Parkinson's indication you said publicly at the JPM conference on January 16th that you would definitely update before the end of the month. It'll be March in two days FYI. Or how about the Rett indication you told shareholders at the ASM last May that there would be an announcement at the Rett conference you were presenting at in just a couple of days? And if you're doing all your own social media posting, I sure hope the company isn't still paying Andrew Barwicki, because I'll not answer shareholders questions for free, you don't need to pay him not to do it.
👍️ 3 👎️ 2 👺 2
BAR123 BAR123 1 일 전
Hoskuld, thanks for the words. Many of us who have been here since 2015 ( without selling during the run ups ) are frustrated. We are not traders but investors. Your words are comforting and yes I believe we have an approvable drug. The only reason for me wanting a new President is to bridge the huge gap between what the company says and has delivered on and Wall Street. You are correct in stating that the IB's want their share. Maybe Dr. M should have wet their beaks and completed a secondary with one of the bigger players to get the support they need. Being a Monday morning quarterback I say yes because I want a higher share price. Have I been able to add shares on the cheap over the last 10 years , no doubt yes. But it is easier to wait for the big pops when the stock is in the $15 area vs. $8. Maybe a great President who has Wall St. backing could accomplish that. At this level it feels like we can collapse with any market downturn and can be cut in half again. I also have a bit of a concern with the growth of the company. We are not adding people but have actually shrunk a bit over the last several months. Currently the headcount is at 49 per linkedin. Down from a high I believe of 52. I know they do have contractors on board but if we are 6-9 months from approval I would think they would be expanding, unless all that comes down to a partnership. Which it should , but 49 employees to handle multi billion dollars in rev starting very soon you would think growth is in order. But in my reality, I think we are for sale and we are keeping the HC low purposely. Do we get the $20B valuation I guess all depends on EMA approval and great data for Schizophrenia. What do you think Fintel will tell us on May 15th. Do you think we get up to 50% institutional ownership? Thanks again for your previous post to me.
👍️ 3 😀 1
Hoskuld Hoskuld 1 일 전
Clint is the VP of Operations. He occasionally speaks with investors because that guy Andrew is pretty useless.
👍️ 5
plexrec plexrec 1 일 전
Bourbon--"stuck at $8 again and again"---do you think we get EMA approval for 2-73 before Y.E. ???? Thoughts ???
👍️0
kund kund 1 일 전
Awaiting the theory that recent price decline is so that
Missling may retain more of the shares from his vested options
thereby it is Bullish......@ some future Febish
Never underestimate TGD when it comes to protecting his own pocket.
👍️ 1 👎️ 2 👺 2
mike_dotcom mike_dotcom 1 일 전
Yea, like that makes sense.
👍️ 1 👎️ 2 🙄 1
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 1 일 전
That's why you are stuck at $8 again and again
👍️ 2 😇 1
mike_dotcom mike_dotcom 1 일 전
That's fantasy land.
🙄 1
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 1 일 전
Please start dreaming about $1249 a share, OK?

I always dreamed that someday AVXL would be an $8 stock and that dream keeps coming true again and again

If you are going to attempt to modify reality using the interconnected universal consciousness, please shoot for the proper target.

👍️ 3 😇 1 🤑 1
LakeshoreLeo1953 LakeshoreLeo1953 1 일 전
You are somewhat late to the Party.
With the Planetary Alignment this week it seems appropriate
that the infamous $15 level was long sought as a break even
by Moon. (You'd have to be a member here longer).
I traded in and out from exiting in the mid/low 20s so
a bit more complicated bookkeeping.

Suffice to say the $0.19 crowd no longer has a 10 bagger
over 10 years.
The perfectly timed $1.04 post NASDAQ seers have a 7X.
The October 2015 OTC conversion crowd are basically even over 10 years.
👍️ 2 👎️ 1 👺 2
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 1 일 전
I to have talked to IR. My experience is that there is no “team” just Clint and he’s unimpressive.

you dont need a team, even one full time IR person is too much for a company with no revenues. this is a function that should be outsourced. hopefully Clint is outsourced, not a full time employee
👍️0
mike_dotcom mike_dotcom 1 일 전
I always dreamed that someday AVXL would be an $8 stock and that dream keeps coming true again and again - often in the same day.
👍️0
kund kund 1 일 전
And WGT says market not giving respect…
👎️ 1 👺 2
loyalinvestor1212 loyalinvestor1212 1 일 전
Everyone that got in at $14… suckers. This stocks an easy one-sell at $14 buy at $4 and you steal everyone else’s money. Job done. 💩
🤢 1
LakeshoreLeo1953 LakeshoreLeo1953 1 일 전
Awaiting the theory that recent price decline is so that
Missling may retain more of the shares from his vested options
thereby it is Bullish......@ some future Febish
👎️ 1 👺 2

최근 히스토리

Delayed Upgrade Clock